# A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

> **NCT04678648** · PHASE1 · RECRUITING · sponsor: **RasCal Therapeutics, Inc.** · enrollment: 134 (estimated)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- RAS Mutation
- Lung Cancer
- Colon Cancer
- Glioblastoma
- Pancreatic Cancer

## Interventions

- **DRUG:** RSC-1255 Dose Escalation
- **DRUG:** RSC-1255 Dose Expansion

## Key facts

- **NCT ID:** NCT04678648
- **Lead sponsor:** RasCal Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-03
- **Primary completion:** 2026-12-15
- **Final completion:** 2027-01-30
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04678648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04678648, "A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04678648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*